Risk of invasive fungal infections in patients with <scp>high‐risk MDS</scp> and <scp>AML</scp> receiving hypomethylating agents
Gee Youn Kim(Rutgers, The State University of New Jersey), Alison W. Loren(University of Pennsylvania), Keith Hamilton(University of Pennsylvania), James K. Mangan(UC San Diego Health System), Mindy G. Schuster(Unknown), Edward A. Stadtmauer(University of Pennsylvania), Alexander E. Perl(University of Pennsylvania), Saar Gill(Parker Institute for Cancer Immunotherapy), Mary Ellen Martin(University of Pennsylvania), Jonathan K. Burns(Hospital of the University of Pennsylvania), David L. Porter(Chapman University), Craig W. Freyer(Hospital of the University of Pennsylvania), Shannon R. McCurdy(Hospital of the University of Pennsylvania), Noelle V. Frey(Hospital of the University of Pennsylvania), Elizabeth O. Hexner(University of Pennsylvania), Selina M. Luger(University of Pennsylvania)
Cited by 28
Related Papers
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplant‐Associated Infection Surveillance Network (TRANSNET)
|Clinical Infectious Diseases|2010|1.5k
Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|1.3k